Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Tobacco Products, Exemptions From Substantial Equivalence Requirements; Correction, 62418 [2011-25967]

Download as PDF 62418 Federal Register / Vol. 76, No. 195 / Friday, October 7, 2011 / Notices comments and suggestions submitted within 60 days of this publication. DEPARTMENT OF HEALTH AND HUMAN SERVICES Robert Sargis, Reports Clearance Officer. Food and Drug Administration [Docket No. FDA–2011–N–0002] [FR Doc. 2011–25947 Filed 10–6–11; 8:45 am] BILLING CODE 4184–01–P Antiviral Drugs Advisory Committee; Notice of Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES AGENCY: ACTION: Food and Drug Administration [Docket No. FDA–2010–N–0646] Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Tobacco Products, Exemptions From Substantial Equivalence Requirements; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of September 12, 2011 (76 FR 56200). The document announced that an information collection had been approved by the Office of Management and Budget (OMB). The document was published with an incorrect expiration date. This document corrects that error. SUMMARY: FOR FURTHER INFORMATION CONTACT: Joyce Strong, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3208, Silver Spring, MD 20993–0002, 301– 796–9148. In FR Doc. 2011–23184, appearing on page 56200, in the Federal Register of Monday, September 12, 2011, the following correction is made: 1. On page 56200, in the first column, under the SUPPLEMENTARY INFORMATION section, the sentence ‘‘The approval expires on August 14, 2014.’’ is corrected to read ‘‘The approval expires on August 31, 2014.’’ jlentini on DSK4TPTVN1PROD with NOTICES SUPPLEMENTARY INFORMATION: Dated: October 3, 2011. David Dorsey, Acting Associate Commissioner for Policy and Planning. [FR Doc. 2011–25967 Filed 10–6–11; 8:45 am] BILLING CODE 4160–01–P VerDate Mar<15>2010 16:33 Oct 06, 2011 Jkt 226001 Food and Drug Administration, HHS. Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public. Name of Committee: Antiviral Drugs Advisory Committee. General Function of the Committee: To provide advice and recommendations to the Agency on FDA’s regulatory issues. Date and Time: The meeting will be held on December 14, 2011, from 8 a.m. to 5 p.m. and on December 15, 2011, from 8 a.m. to 1 p.m. Location: FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center (rm. 1503), 10903 New Hampshire Ave., Silver Spring, MD 20993–0002. Information regarding special accommodations due to a disability, visitor parking and transportation may be accessed at: https://www.fda.gov/Advisory Committees/default.htm; under the heading ‘‘Resources for You,’’ click on ‘‘Public Meetings at the FDA White Oak Campus.’’ Please note that visitors to the White Oak Campus must enter through Building 1. Contact Person: Paul Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, rm. 2417, Silver Spring, MD 20993–0002, 301 796–9001, FAX: 301 847–8533, e-mail: AVAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800– 741–8138 (301–443–0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting. Agenda: On December 14 and 15, 2011, the committee will discuss PO 00000 Frm 00083 Fmt 4703 Sfmt 4703 pathways for the development of drugs intended to treat variola virus infection (smallpox) in the event of an outbreak, including the use of animal models of other orthopoxviruses (the group of viruses that includes smallpox) as potential evidence of efficacy. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at https://www.fda.gov/ AdvisoryCommittees/Calendar/default. htm. Scroll down to the appropriate advisory committee link. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before November 30, 2011. Oral presentations from the public will be scheduled between approximately 3 p.m. and 4 p.m. on December 14, 2011. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 21, 2011. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 22, 2011. Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Paul Tran at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at https://www.fda.gov/Advisory Committees/AboutAdvisoryCommittees. E:\FR\FM\07OCN1.SGM 07OCN1

Agencies

[Federal Register Volume 76, Number 195 (Friday, October 7, 2011)]
[Notices]
[Page 62418]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-25967]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0646]


Agency Information Collection Activities; Announcement of Office 
of Management and Budget Approval; Tobacco Products, Exemptions From 
Substantial Equivalence Requirements; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
that appeared in the Federal Register of September 12, 2011 (76 FR 
56200). The document announced that an information collection had been 
approved by the Office of Management and Budget (OMB). The document was 
published with an incorrect expiration date. This document corrects 
that error.

FOR FURTHER INFORMATION CONTACT: Joyce Strong, Office of Policy, Food 
and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3208, 
Silver Spring, MD 20993-0002, 301-796-9148.

SUPPLEMENTARY INFORMATION: In FR Doc. 2011-23184, appearing on page 
56200, in the Federal Register of Monday, September 12, 2011, the 
following correction is made:
    1. On page 56200, in the first column, under the SUPPLEMENTARY 
INFORMATION section, the sentence ``The approval expires on August 14, 
2014.'' is corrected to read ``The approval expires on August 31, 
2014.''

    Dated: October 3, 2011.
David Dorsey,
Acting Associate Commissioner for Policy and Planning.
[FR Doc. 2011-25967 Filed 10-6-11; 8:45 am]
BILLING CODE 4160-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.